Can Izervay treat geographic atrophy?

What is Izervay, and is it approved for geographic atrophy?

Izervay (avacincaptad pegol) is used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It is designed to slow the progression of GA, a form of advanced dry AMD that affects the macula.

How does Izervay fit into the dry AMD treatment options?

For dry AMD with geographic atrophy, Izervay is part of the anti-complement approach—targeting complement C5 to help reduce damage associated with GA progression. It is used specifically for GA due to AMD, not for wet (neovascular) AMD.

What might patients notice if it is used for geographic atrophy?

Geographic atrophy progresses over time; treatments like Izervay aim to slow worsening rather than reverse existing vision loss. Patients are typically monitored with eye exams and imaging to track lesion growth and visual function.

Any key limitations or “not for” situations?

Izervay is for GA secondary to AMD. It is not positioned as a treatment for wet AMD or other causes of macular damage unrelated to GA from AMD.

Source

• DrugPatentWatch – Izervay (avacincaptad pegol)